Class summary at a glance.

Every drug in the Norepinephrine-Dopamine Reuptake Inhibitor (NDRI) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $479.3Mcombined across class
Total Rx claims: 14.9M4.2M unique beneficiaries
Generic mfrs (active): 26across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Bupropion

Brand: BUPROPION HYDROCHLORIDE (SR) · 14.9M Part D claims (CY24) · 4.2M beneficiaries · First FDA approval: 1996-11-15

26 generic mfrs 0 plans require PA

Low NADAC$0.068

→

Avg plan cost$0.272

Part D spend $479.3M 4× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.